Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
SEATTLE, Dec. 01, 2016 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its nCounter Vantage 3D™ assays, a portfolio of panels that enable simultaneous analysis of DNA, RNA, and protein were listed by The Scientist as a Top 10 Innovation of 2016. Now in its ninth year, The Scientist top innovation award program recognizes new products revolutionizing life science research.
NanoString announced thirteen nCounter Vantage 3D panels in April 2016 at the American Association for Cancer Research Annual Meeting. This includes seven panels for RNA analysis, two panels for gene fusion analysis, three panels for protein analysis, and the first of three new panels for DNA analysis. The Vantage 3D™ protein panels can be combined with existing nCounter gene expression panels including the PanCancer panels for simultaneous analysis of RNA and Protein.
“Many areas of life science research, including biomarker discovery and drug development, involve measurements of DNA, RNA, and proteins. Analyzing these different types of biomolecules typically requires three separate platforms. However, the simultaneous digital quantification enabled by our 3D Biology™ approach addresses many of the challenges inherent in sequential testing,” said Joe Beechem, Ph.D., senior vice president of research and development at NanoString Technologies. “Our Vantage 3D assays offer an unprecedented integration of three tests into one experiment. By eliminating the need to divide small samples among different experiments, researchers can extract more data from each precious sample.”
“This year’s crop of Top 10 Innovation submissions contained some great products that posed a real challenge to our panel of experts, tasked by us with singling out the best and brightest,” said Editor-in-Chief Mary Beth Aberlin. “As usual, the independent judges delivered and highlighted innovations that truly have the potential to transform the life sciences.”
For more information about The Scientist’s Top 10 Innovations 2016 and for a full list of winners, visit: www.the-scientist.com/2016Top10.
This is the second time in recent years that one of NanoString’s products has been honored as a Top 10 Innovation. In 2013, The Scientist also listed NanoString’s Prosigna® Breast Cancer Prognostic Gene Signature Assay in the Top 10 Innovations list. The Prosigna Assay assesses a patient’s risk of distant breast cancer recurrence at 10 years in postmenopausal women with node-negative (Stage I or II), or node-positive (Stage II), hormone receptor-positive breast cancer by examining the gene expression profile of the patient’s tumor cells.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,350 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, 3D Biology, and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Contact: Doug Farrell Vice President, Investor Relations & Corporate Communications [email protected] Phone: 206-602-1768
